• Теги
    • избранные теги
    • Компании147
      • Показать ещё
      • Показать ещё
      Страны / Регионы74
      • Показать ещё
      Международные организации3
Выбор редакции
15 ноября, 16:53

Sanofi Opts into Alnylam's Fitusiran Hemophilia Program in U.S.

Alnylam Pharmaceuticals, Inc. (ALNY) announced that Genzyme, the specialty care global business unit of Sanofi (SNY), has elected to opt in to co-develop and co-commercialize fitusiran in the United States, Canada and Western Europe.

Выбор редакции
Выбор редакции
03 ноября, 15:45

Alnylam (ALNY) Q3 Loss Wider than Expected, Revenues Up

Alnylam (ALNY) reported a loss of $1.21 per share in the third quarter of 2016 on revenues of $13.7 million.

31 октября, 16:14

Sanofi (SNY) Beats Earnings, Revenues Rise Y/Y; Ups View

Sanofi (SNY) reported third-quarter 2016 business earnings of $1.00 per American Depositary Share, which beat the Zacks Consensus Estimate of 86 cents by 16.28%.

28 октября, 17:21

BioMarin (BMRN) Q3 Loss Narrows Y/Y, Pipeline in Focus

BioMarin Pharmaceutical (BMRN) reported a loss of 18 cents per share in the third quarter of 2016, narrower than the year-ago loss of 44 cents.

08 сентября, 16:42

Alnylam (ALNY) Reports Positive Phase I Data on ALN-AS1

Alnylam Pharmaceuticals, Inc. (ALNY) announced positive interim results from an ongoing phase I study, evaluating its pipeline candidate, ALN-AS1.

05 августа, 18:34

BioMarin (BMRN) Posts Narrower Q2 Loss, Sales View Upped

BioMarin Pharmaceutical (BMRN) reported a narrower-than-expected second-quarter 2016 loss of 11 cents per shares; revenues beat estimates while the view was upped.

02 августа, 00:19

Sanofi (SNY) Posts In-Line Q2 Earnings, Revenues Down Y/Y

Sanofi (SNY) reported second-quarter 2016 business earnings of 74 cents per American Depositary Share, in line with the Zacks Consensus Estimate.

07 июля, 17:09

Sanofi Starts Olipudase Alfa Study, Praluent Ok'd in Japan

Sanofi's (SNY) begins dosing of the first adult patient in a phase II/III study on olipudase alfa; Praluent gains approval in Japan.

Выбор редакции
05 мая, 17:20

Ionis Incurs Wider-than-Expected Loss in Q1, Stock Down

Ionis Pharmaceuticals (IONS) reported a wider-than-expected first-quarter 2016 loss of 52 cents; revenues plunged year over year.

03 мая, 17:38

Alnylam (ALNY) Reports Wider-than-Expected Loss in Q1

Alnylam (ALNY) reported a loss of $1.21 per share in the first quarter of 2016 on revenues of $7.3 million.

29 апреля, 20:32

BioMarin (BMRN) Reports Narrower-than-Expected Q1 Loss

BioMarin (BMRN) reported a loss of 35 cents per share in the first quarter of 2016, narrower than the Zacks Consensus Estimates of a loss of 85 cents.

Выбор редакции
29 апреля, 11:11

Sanofi, Medivation dig in for big biotech takeover battle

PARIS (Reuters) - Sanofi and its takeover target Medivation dug in for trench warfare on Friday, with the French drugmaker confident of winning over investors and the U.S. cancer firm insisting it was better off staying independent.

06 апреля, 17:37

ПРООН заключила контракты с пятью компаниями на поставку препаратов от детской гемофилии на $6,955 млн

Программа развития ООН (UNDP) заключила контракты с пятью компаниями на поставку 15-ти препаратов для лечения детской гемофилии на $6,955 млн (с учетом логистики).

Выбор редакции
18 марта, 22:20

Bayer's Kovaltry Gets Approval in the U.S. for Hemophilia A

Bayer's (BAYRY) hemophilia drug, Kovaltry, was approved in the U.S. for the treatment of children and adults with hemophilia A.

11 марта, 00:45

Alnylam Begins Study for Primary Hyperoxaluria Type 1

Alnylam Pharmaceuticals (ALNY) announced that it has initiated a phase I/II study on ALN-GO1 for the treatment of primary hyperoxaluria type 1.

Выбор редакции
04 марта, 23:45

Sanofi/Genzyme Present Positive Pompe Disease Study Data

Sanofi (SNY) and its specialty care global business unit, Genzyme, presented data from a phase I/II study on late-onset Pompe disease candidate neoGAA.